Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation ...

The transaction builds on a three-way partnership between Sanofi, Orano Med, and RadioMedix – signed in September with a €100 ...

Sanofi SNY announced that it has entered into an agreement with France-based cancer biotech Orano Med to jointly develop next ...

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, ...

Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology ...

The new entity will operate under the brand of Orano Med, a subsidiary of Orano Group. Sanofi already has a relationship with Orano Med. Last month, the Paris-based pharmaceutical giant licensed ...

Sanofi has partnered with Orano Med, a subsidiary of Orano Group, to develop radioligand therapies for rare cancers. Sanofi ...

The French drugmaker will invest 300 million euros into a new entity that will develop lead isotope-based therapies for ...

Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers. The companies plan to invest ...

Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the ...

Sanofi & Orano join forces to accelerate the development of develop next-generation radioligand medicines: Paris Friday, October 18, 2024, 10:00 Hrs [IST] Sanofi and Orano Med, a ...